Christopher Bryant, MD
Gynecologic Oncology · Orlando, FLNPI 1801836366
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,000 of the $28,313 with a category attached, or 67.1%. Aspira Women's Health Inc accounts for 73.7% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $17,542 and has fallen 99.1% since, to $165 in 2025.
Across 83 payments — averaging $341.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aspira Women's Health Inc$21K
- Momentis Surgical Inc.$5K
- Intuitive Surgical$381
- AbbVie$268
- Johnson & Johnson$264
- Tesaro, Inc.$189
- plus $1K from 26 others
Across 6 payments — averaging $3863.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$23K
What the payments were for
- Consulting fees$5,96321%
- Speaking & faculty fees$19,00067%
- Food & beverage$3,35112%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aspira Women's Health Inc | 16 | $20,870 |
| Momentis Surgical Inc. | 8 | $5,018 |
| Intuitive Surgical | 7 | $381 |
| AbbVie | 3 | $268 |
| Johnson & Johnson | 3 | $264 |
| Tesaro, Inc. | 5 | $189 |
| AstraZeneca | 2 | $136 |
| Medical Device Business Services, Inc. | 1 | $129 |
| Hologic Sales And Service, LLC | 2 | $125 |
| Gauss Surgical Inc. | 1 | $98 |
| Smith+Nephew | 1 | $98 |
| Merck | 4 | $77 |
| Genentech USA, Inc. | 1 | $64 |
| Procept Biorobotics Corporation | 1 | $61 |
| Astellas Pharma US Inc | 3 | $60 |
| Applied Medical Resources Corporation | 1 | $51 |
| Pfizer | 3 | $50 |
| Eisai Inc. | 2 | $46 |
| Daiichi Sankyo Inc. | 3 | $43 |
| Clovis Oncology, Inc. | 2 | $35 |
| Tersera Therapeutics LLC | 2 | $32 |
| Davol Inc. | 1 | $29 |
| GSK | 1 | $29 |
| Cumberland Pharmaceuticals, Inc. | 2 | $23 |
| Boston Scientific | 1 | $22 |
| Myriad Genetic Laboratories, Inc. | 1 | $20 |
| Seagen Inc. | 1 | $19 |
| Mimedx Group, Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Olympus America Inc. | 1 | $16 |
| Bolder Surgical LLC | 1 | $15 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OVA1$20,870
- Anovo Surgical System$4,735
- Orilissa$249
- STRATAFIX$136
- Da Vinci Surgical System$133
- VISTASEAL$129
- LYNPARZA$125
How this compares
$28,313 in reported general payments places this provider in the 75th percentile of 117 gynecologic oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $1,831 |
| Clobetasol Propionate | 23 | $465 |
| Ondansetron Hcl | 59 | $421 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 53 | $296 |
| Gabapentin | 75 | $154 |
| Ibuprofen | 42 | $145 |
| Methocarbamol | 50 | $138 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $50 | $1,83111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 117 gynecologic oncology providers in Florida.
Other gynecologic oncology in Orlando
- Robert HollowayOrlando$432K
- Shelly SewardOrlando$349K
- Nathalie McKenzieOrlando$223K
- Jessica KennardOrlando$39K
- Veronica SchimpOrlando$5K
- James KendrickOrlando$3K
- Bradley MonkWest Palm Beach$2.5M
- Martin MartinoJacksonville$957K
- Brian SlomovitzFort Lauderdale$519K
- Ricardo EstapeMiami$457K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.